Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Gilead and insitro announce strategic collaboration to discover and develop novel therapies for NASH

April 16, 2019 0

Gilead and insitro Collaborate to Discover and Develop Novel Therapies for NASH using ISH Gilead Sciences (GILD) and insitro entered into a strategic collaboration to discover and develop treatments for nonalcoholic steatohepatitis (NASH). NASH A chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the …

Regeneron and Alnylam collaborative agreement will benefit these firms so...

Sangamo’s stock price Soars 52% in pre-market hours on hemophilia...

Aimmune Therapeutics’ product AR101 for the treatment of peanut allergy...

The FDA approves the first ever postpartum depression product. Positive...

Atossa Genetics’ news that staged a huge Rally of this...

Spark Therapeutics to be acquired by Roche at $113.47 UP $61.91

Merck’s product Keytruda and Exelixis’ product Cabometyx are both winners

RegenxBio: An analyst and investor event focused on the firm’s...

Successful results were announced by uniQure for its gene therapy,...

RegenxBio product RGX-181 has been granted FDA Rare Pediatric Disease...

OncoCyte liquid biopsy proves its accuracy and superiority in the...

CompuGen demonstrates the importance of its product COM701 targeting PVRIG...

Another drug approval for Exelixis. Why Alnylam’s stock is under...

Why the new approval of Exelixis’ blood pressure drug Minnebro...

The importance of the FDA granting Fast Track Designation to...

Rhythm Pharmaceutical: Updates on trial results from genetic-derived obesity

Gilead: On the road towards realizing its goals. A new...

Agenus: Signing a lucrative and rewarding agreement with Gilead

AstraZeneca: Excellent collaborations. Moderna Therapeutics: Turning public. Will Prohost add...

Today’s Highlights

Novartis: More promising data from a Phase 3 trial with AveXis’ gene therapy Zolgensma® for Spinal Muscular Atrophy Type 1

April 17, 2019 0

Novartis Has More Promising Data from Their Phase 3 Gene Therapy Trial with AveXis AveXis, a …

$Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture$

Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture

April 10, 2019 0

Amgen (AMGN) and UCB announced that the U.S. Food and Drug Administration (FDA) has granted approval …

The Amgen/Novartis story. A little curiosity about Alder Biopharmaceuticals.

April 8, 2019 0

In May 2018 Novartis (NVS) and Amgen (AMGN) announced that their novel migraine drug Aimovig™ was been …

Novartis’ Revolution: A new dimension and Prohost expectations

April 1, 2019 0

The market is outperforming today. There is important news today about Novartis; part of which we …

Seattle Genetics: Why a selloff following good news

March 29, 2019 0

Following Seattle Genetics' (SGEN) and Astellas Pharma's announcement of positive results, from pivotal trial of the conjugated monoclonal antibody …

Why Agios Pharmaceuticals’ product TIBSOVO® was granted FDA Breakthrough Therapy designation. The FDA approves Jazz Pharmaceuticals’ product Sunosi

March 27, 2019 0

The uncontrolled blowing toxic wind contaminates this country’s environment, it brings down the oversold scientifically solid …

Bluebird bio opens a state-of-the art gene and cell therapy manufacturing facility in Durham, NC

March 22, 2019 0

Governor Cooper to cut ribbon on bluebird bio facility Bluebird bio (BLUE) announced today, in its …

Biogen discontinued its Alzheimer’s disease drug Aducanumab. The usual selloff followed

March 21, 2019 0

Biogen’s (BIIB) decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE which is designed …

Gene therapy: Speeding down the road towards offering cures. A small firm might have some good news

March 12, 2019 0

We love to read news about gene therapy as it is the only possibility for curing …

Exelixis moves more products into clinical trials. Alnylam’s product Givosiran demonstrates efficacy in Acute Hepatic Porphyria (AHP). Why investors have caused a stock selloff.

March 6, 2019 0

Thanks to abundant cabozantinib sales’ revenues Exelixis (EXEL) is advancing a new generation of its medicines …

The Week in Review

The Week in Review #40

April 16, 2019 0

Conquering NASH Gilead and Novo Nordisk Conquering NASH What was Gilead Sciences' (GILD) announcement at …

During the Departed Week

March 19, 2019 0

The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week …

Good news and setbacks during the departed week

March 5, 2019 0

The Week in Review #38 SYNOPSIS Good News and Setbacks During the Departed Week from the …

The Week in Review #37

February 19, 2019 0

From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation …

Now You See It, Now You Don’t

January 28, 2019 0

Now You See it, Now You Don’t Deliberate Omissions of Real Facts Real facts might be …

Politics and the Market

December 11, 2018 0

The Week in Review #35 Politics and the Market The market tumbled today as Theresa May, …

Improving on immunotherapy and preventing one of its serious side effects

November 13, 2018 0

The Week in Review #34 Improving on Immunotherapy and preventing one of its serious side effects. …

We call it the bad market

October 30, 2018 0

The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of …

Positive News

October 22, 2018 0

The Week in Review #32 POSITIVE NEWS PROTEOSTASIS THERAPEUTICS Cystic Fibrosis Two days ago, a clinical-stage …

Outperformance, underperformance and volatility

October 2, 2018 0

The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY …

Prohost Letters

Prohost Letter #430

April 5, 2019 0

Rheumatoid Arthritis and Gilead The FINCH 1 trial: Has it reached its primary endpoints? How did …

End of the Year Decisions ~ Part 4

March 14, 2019 0

Prohost Letter #429 End of the Year Decisions ~ Part 4 We picked for our portfolio …

End of the Year Decisions ~ Part 3

February 10, 2019 0

Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this …

End of the Year Decisions Part 2

January 24, 2019 0

Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected …

End of the Year Decisions ~ Part 1

January 15, 2019 1

Prohost Letter #426 End of the Year Decisions ~ Part 1 We decided to make this …

The NEW Prohost Portfolio for 2019

January 3, 2019 0

The NEW Prohost Portfolio Small Important Changes We are making some very small but important changes …

When common sense fails to explain market performance

December 3, 2018 0

Prohost Letter #425 When Common Sense Fails to Explain the Market Performance It is not unusual …

Following the Stars. Less Science and More Logic

October 14, 2018 0

Prohost Letter #424 Following the Stars Less Science and More Logic We reiterate that while a …

Victims of fear and misunderstanding

August 1, 2018 0

ProhostLetter #423 TOMORROW’S THERAPEUTICS TODAY For a more or less fair evaluation of biotechnology and pharmaceutical …

New stock selection and re-evaluation

June 8, 2018 0

Prohost Letter #422 SUMMARY OF THE PAST ISSUE ARTICLE - REVISITING PROMISING FIRMS (PART1) - The …